Abstract: Objective: The aim of this study was to clarify the role of IL-33 in tumor progression. Methods: Surgical specimens from 81 patients with squamous cell carcinoma of the tongue were studied using immunohistochemistry. Primary tumor sections were analyzed for IL-33 and ST2 expression. To examine the influence of IL-33 on the microenvironment of the tumor, we determined the mast cell density (MCD) and microvessel density of the stroma. Results: Patients with high IL-33 expression had a significantly worse prognosis (p = 0.004). IL-33 expression was significantly elevated in patients with local and nodal recurrence (p = 0.014 and p = 0.019). ST2 expression was also associated with a worse prognosis (p = 0.024) and was significantly elevated in patients with nodal recurrence (p = 0.004). MCD was associated with worse prognosis (p = 0.038) and correlated significantly with IL-33 expression (r = 0.626, p < 0.001). Micovessels in the stroma were significantly increased in the high IL-33 group (p < 0.001). Conclusion: These data suggest that the IL-33/ST2 axis contributes to tumor aggressiveness and affects the tumor microenvironment. Immunohistochemical evaluation of IL-33 and ST2 is useful for identifying patients at a high risk for poor prognosis.
We agree with the reviewer' opinion. We added the information for ethical aspect to line 105, 106 in materials and methods part.
A multivariant analysis is desired to confirm that IL33expression is an independent prognostic factor.
A cox proportional hazards regression analysis of clinical factors, including sex, age, histologic type, T classification, N classification, expression of IL-33, expression of ST2 and MCD was performed. Univariate analyses were done initially, and then clinical factors that were identified as significantly associated with the disease-free survival rate were included in a multivariate analysis.
The univariate analysis demonstrated that IL-33, ST2, and MCD were significant predictors for prognosis. However, there was no significant predictor in the multivariate analysis. We consider that this is because IL-33 expression correlated with ST2 expression and IL-33 expression also correlated with MCD. 
A cox proportional hazards regression analysis of prognostic factors associated with the disease-free survival rate

Response
We thank the reviewer for this excellent suggestion and finding our data convincing. We answered the questions that were found in reviewer' text.
"2.2. Immunohistochemical analysis
The specimens, including the primary tumors, were fixed in 10% formalin solution and embedded in paraffin."
This sentence means that all specimens were not primary lesions, that is tongue carcinoma. If so, were other specimens obtained from lymph node? Show us percentages of specimens from primary lesion. In addition, was there any difference between primary and metastatic lesion?
Sorry for our sentence which caused misunderstanding. We meant that all specimens were the primary tumors. We didn't evaluate the other specimens like lymph node.
We have corrected the sentence at line 121 intelligibly.
Concerning LN metastasis, did you estimate an extranodal extension? If so, was that related to high IL-33?
This is a very good point. Although an extranodal extension also weighs on our mind, we did not estimate it in this study. However, most of IL-33 positive patients developed regional LN recurrences or residual diseases. So, we speculate IL-33 might have contributed to extracapsular invasion.
Is there any different prognosis among the high IL-33patients with/ without postoperative adjuvant therapy?
To examine the relationship of the prognosis of the high IL-33 patients with postoperative adjuvant therapy, Kaplan-Meier survival analysis was performed and differences between curves were analyzed using the log-rank test. Of the 41 patients assigned to the high IL-33 group, 14 patients underwent postoperative treatment. Although the patients with postoperative treatment tended to have better prognosis than those without postoperative treatment, there was no significant difference between the two (p = 0.145). 
Expression of interleukin
Introduction 51 52
Tongue squamous cell carcinoma (SCC) is one of the most common head and neck 53 cancers. Prognosis is associated with clinical stage, particularly nodal status. Therefore, the 54 expression of metastasis-related factors such as matrix metalloproteinases, syndecans, and 55 vascular endothelial growth factor predicts the treatment outcome of patients with tongue 56 SCC [1] [2] [3] [4] . Tongue SCC is associated with inflammation in the oral cavity, which is mediated 57
by chronic trauma such as smoking, alcohol consumption, and periodontal disease and is 58 associated with oral carcinogenesis [5] . Moreover, inflammation promotes cancer 59 development and progression through its effects on the tumor microenvironment [6] . 60
Inflammatory mediators and specific cell types influence the migration, invasion, and 61 metastasis of tumor cells [6] . Therefore, efficacious therapies must be developed for targeting 62 inflammation in patients with cancer. 63
Interleukin (IL)-33 is a member of the IL-1 family and functions as a ligand for ST2, 64 which is a member of the IL-1 receptor family. IL-33 is expressed by many cell types, 65 including epithelial cells, endothelial cells, smooth muscle cells, fibroblasts, and activated 66 macrophages [7] . In contrast, mast cells (MCs), Th2 cells, eosinophils, basophils, epithelial 67 cells, and endothelial cells express ST2 [8] [9] [10] [11] [12] . Unlike other members of the IL-1 family, the 68 cleavage site for caspases is located within the IL-1-like domain of IL-33, and the cleavage 69 products are biologically inactive. 70
Biologically active, full-length IL-33 is released when cells sense inflammatory signals or 71 undergo necrosis. Therefore, IL-33 acts as an endogenous danger signal or "alarmin" 72 [8, 13, 14] . Binding of extracellular IL-33 to ST2 preferentially induces Th2-type immune 73 responses with concomitant expression of Th2-associated cytokines [7] . It is clear that the 74 potency of IL-33 for activating several immunocytes probably impacts inflammation. For 75 example, IL-33 is expressed by patients with chronic gastritis, chronic hepatitis, and 76 inflammatory bowel disease [15] [16] [17] . Inflammatory diseases increase the risk of developing 77 cancer, suggesting that IL-33 may play an important role in cancer pathogenesis [18, 19] . 78 IL-33 affects the phenotype of cell types that express the transmembrane isoform of ST2. 79
The inflammatory component of a neoplasm may include a diverse leukocyte population, and 80 ST2 is expressed on many of these inflammatory cells, including MCs, macrophages, 81 dendritic cells, eosinophils, and neutrophils [8, 20] . Among the inflammatory cells in the 82 stroma of the tumor, MCs are important because they secrete cytokines and chemokines, and 83 influence the phenotypes of other cells through these soluble mediators as well as through 84 cell-cell interaction. Moreover, MCs reside in the connective tissue surrounding tumors, and 85 the accumulation of MCs is often associated with poor prognosis [21, 22] . IL-33 is a potent 86 activator of MCs and induces their degranulation and maturation, promotes survival, and 87 induces the production of several proinflammatory cytokines [9, 23] . Therefore, it is 88 reasonable to assume that IL-33 contributes significantly to the malignant potential of tumor 89 cells through the formation of an inflammatory tumor microenvironment. 90
We reported the carcinogenic role of activation-induced cytidine deaminase (AID), which 91 is induced by an inflammatory environment [24] . However, the expression of AID does not 92 correlate with the progression of tongue SCC, which diverted our attention to IL-33. 93
Inflammation mediated by tobacco smoking, which is associated with tongue SCC, induces 94 the expression of IL-33/ST2 in mice [25] . In the present study, we determined the expression 95 of IL-33 in patients with tongue SCC using immunohistochemistry and assessed the 96 relationship between the expression of IL-33 and prognosis of tongue SCC. Furthermore, to 97 evaluate the influence of IL-33 on the tumor microenvironment, we determined the density of 98
MCs in the stroma surrounding the tumor. 99 Weidner et al [27] . Three areas with the highest MVD were selected in a 40× to 100× field. between IL-33 and ST2 expression and MCD was evaluated using Spearman's rank 166 correlation coefficient. Survival curves were evaluated using the Kaplan-Meier method, and 167 differences between curves were analyzed using the log-rank test. IL-33 expression in 168 relation to MVD was analyzed using the Mann-Whitney U test. A p value of <0.05 was 169 considered statistically significant. 170 horny layers ( Fig. 1A and 1B) . In contrast, IL-33 was detected in the nuclei and cytoplasm of 178 SCC cells (Fig. 1C) . ST2 expression was most prominent in the membrane and cytoplasm of 179 the tumor cells (Fig. 1D ). IL-33 and ST2 expression were observed in 100% and 95.1% of the 180 samples, respectively. The mean expression scores for IL-33 and ST2 in the tumor cells were 181 41.59% ± 23.89% and 22.14% ± 19.29%, respectively. 182 183
Materials and methods
MCD 184 185
MCs were detected by staining with the anti-tryptase antibody in all samples, and they 186 were located in the stroma at the margins of the tumors (Fig. 1E ). The mean MCD was 187 12.54% ± 11.60%. 188 
Association of IL-33 and ST2 expression and MCD with disease-free survival 195 196
To evaluate the prognostic value of IL-33 and ST2 expression and MCD in patients with 197 tongue SCC, patients were stratified into high and low groups as described in Methods. The 198 median expression scores for IL-33 and ST2 were 46% and 14%, respectively, and 9% for 
Relationship between clinicopathological features and expression of IL-33, ST2, and 212
MCD 213 214
The relationship between immunohistochemical data and clinicopathological factors of the 215 81 patients, including age, sex, T classification, N classification, clinical stage, local 216 recurrence, nodal recurrence, and distant metastatic recurrence, was evaluated using Fisher's 217 exact test and the chi-square test (Table 1) . Local recurrence was significantly more frequent 218 among patients in the high IL-33 group than among those in the low IL-33 group. IL-33 and 219 ST2 expression and MCD were significantly associated with nodal recurrence. A higher 220 frequency of nodal recurrence associated significantly with the high IL-33, ST2, and MCD 221 groups, but not with the low groups. There were no other significant differences in 222 clinicopathological features between the low and high IL-33, ST2, and MCD groups. 223
Relationship between IL-33 expression and MVD 225 226
Vascular endothelial cells reacted specifically with the antibody against CD34. The 227 microvessels were detected as scattered structures in the stroma of the tumor (Fig. 1F) . 228
MVDs in all patients ranged from 7 to 75 (mean, 34.41 ± 16.46). The correlation between IL-229 33 expression and MVD is shown in Table 2 . MVD was significantly higher in the high IL-230 33 group than in the low IL-33 group (p < 0.001). Little is known about the role of IL-33 in the pathogenesis and progression of carcinomas 235 [18, 19] . This is the first study, to our knowledge, that demonstrates IL-33 expression in 236 tongue SCC and suggests its role in the progression of this tumor. We detected the expression 237 of IL-33 and ST2 in patients with tongue SCC by immunohistochemistry and found that the 238 expression of IL-33 was significantly correlated with poor prognosis. 239
We do not go further for the molecular mechanism which is attributable to the prognostic 240 value of IL-33 in this study, however, one of possible mechanism for IL-33-mediated 241 malignant progression could be an activation of ST2 downstream signal transduction such as 242 nuclear factor-κB (NF-κB). The IL-33/ST2 axis leads to activation of NF-κB [8, 20, 28] , 243 which is a key inducer of innate immunity and inflammation and has emerged as an 244 important endogenous tumor promoter [6, 29] . NF-κBactivates the expression of genes 245 encoding inflammatory cytokines, adhesion molecules, enzymes of the prostaglandin-246 synthesis pathway, inducible nitric oxide synthase, and angiogenic factors. Thus, activation 247 of NF-κB through the IL-33 signaling pathway may cause cancer progression. [8, 20] . High levels of Th2 cytokines are observed in the tumor 251 microenvironment and peripheral blood of patients with certain cancers [30] . Moreover, 252
analysis of ST2-deficient mice demonstrates that the Th2-associated immune response is 253 inhibited in the absence of IL-33/ST2 signaling, leading to delayed induction of mammary 254 tumors and slower tumor growth and progression [31, 32] . 255
In addition, IL-33 induces angiogenesis and vasopermeability [33] . Our present study 256 IgE-primed MCs and enhances their maturation and survival [8, 20] . The MCD generally 265 correlates with poor outcome in patients with tongue SCC [34, 35] . Furthermore, other studies 266 reveal that IL-33 activates macrophages, dendritic cells, eosinophils, and neutrophils [8, 20] . 267
These cells play important roles in enhancing an inflammatory environment that promotes 268 tumor growth in the surrounding tissue [6] . IL-33 may recruit these inflammatory cells to the 269 stroma of the tumor, subsequently enhancing tumor aggressiveness. 270
In conclusion, the high expression level of IL-33 is a risk factor for poor prognosis in Differences between the curves were analyzed using the log-rank test. Disease-free survival 419 rates in relation to IL-33 expression (A), ST2 expression (B), and MCD (C). 420
Introduction
Tongue squamous cell carcinoma (SCC) is one of the most common head and neck cancers. Prognosis is associated with clinical stage, particularly nodal status. Therefore, the expression of metastasis-related factors such as matrix metalloproteinases, syndecans, and vascular endothelial growth factor predicts the treatment outcome of patients with tongue SCC [1] [2] [3] [4] . Tongue SCC is associated with inflammation in the oral cavity, which is mediated by chronic trauma such as smoking, alcohol consumption, and periodontal disease and is associated with oral carcinogenesis [5] . Moreover, inflammation promotes cancer development and progression through its effects on the tumor microenvironment [6] .
Inflammatory mediators and specific cell types influence the migration, invasion, and metastasis of tumor cells [6] . Therefore, efficacious therapies must be developed for targeting inflammation in patients with cancer.
Interleukin (IL)-33 is a member of the IL-1 family and functions as a ligand for ST2, which is a member of the IL-1 receptor family. IL-33 is expressed by many cell types, including epithelial cells, endothelial cells, smooth muscle cells, fibroblasts, and activated macrophages [7] . In contrast, mast cells (MCs), Th2 cells, eosinophils, basophils, epithelial cells, and endothelial cells express ST2 [8] [9] [10] [11] [12] . Unlike other members of the IL-1 family, the cleavage site for caspases is located within the IL-1-like domain of IL-33, and the cleavage products are biologically inactive.
Biologically active, full-length IL-33 is released when cells sense inflammatory signals or undergo necrosis. Therefore, IL-33 acts as an endogenous danger signal or "alarmin" [8, 13, 14] . Binding of extracellular IL-33 to ST2 preferentially induces Th2-type immune responses with concomitant expression of Th2-associated cytokines [7] . It is clear that the potency of IL-33 for activating several immunocytes probably impacts inflammation. For example, IL-33 is expressed by patients with chronic gastritis, chronic hepatitis, and inflammatory bowel disease [15] [16] [17] . Inflammatory diseases increase the risk of developing cancer, suggesting that IL-33 may play an important role in cancer pathogenesis [18, 19] .
IL-33 affects the phenotype of cell types that express the transmembrane isoform of ST2.
The inflammatory component of a neoplasm may include a diverse leukocyte population, and ST2 is expressed on many of these inflammatory cells, including MCs, macrophages, dendritic cells, eosinophils, and neutrophils [8, 20] . Among the inflammatory cells in the stroma of the tumor, MCs are important because they secrete cytokines and chemokines, and influence the phenotypes of other cells through these soluble mediators as well as through cell-cell interaction. Moreover, MCs reside in the connective tissue surrounding tumors, and the accumulation of MCs is often associated with poor prognosis [21, 22] . IL-33 is a potent activator of MCs and induces their degranulation and maturation, promotes survival, and induces the production of several proinflammatory cytokines [9, 23] . Therefore, it is reasonable to assume that IL-33 contributes significantly to the malignant potential of tumor cells through the formation of an inflammatory tumor microenvironment.
We reported the carcinogenic role of activation-induced cytidine deaminase (AID), which is induced by an inflammatory environment [24] . However, the expression of AID does not correlate with the progression of tongue SCC, which diverted our attention to IL-33.
Inflammation mediated by tobacco smoking, which is associated with tongue SCC, induces the expression of IL-33/ST2 in mice [25] . In the present study, we determined the expression of IL-33 in patients with tongue SCC using immunohistochemistry and assessed the relationship between the expression of IL-33 and prognosis of tongue SCC. Furthermore, to evaluate the influence of IL-33 on the tumor microenvironment, we determined the density of MCs in the stroma surrounding the tumor.
Materials and methods
Patients and specimens
This study included 81 patients who were diagnosed with tongue SCC. Informed consent was obtained from all patients in accordance with our institutional guidelines. The patient characteristics are presented in Table 1 
Immunohistochemical analysis
All specimens were the primary tumors. They were fixed in 10% formalin solution and embedded in paraffin. Serial 3-μm-thick sections were cut from each block, dewaxed, and rehydrated. Antigen retrieval was performed by heating slides for 30 min in citrate buffer (pH 6.0) at 90ºC, cooling for 20 min, and washing. Endogenous peroxidase was quenched with methanol and 3% H 2 O 2 for 10 min, followed by incubation with Protein Block Serum (DakoCytomation, Glostrup, Denmark) to decrease nonspecific binding. Then, the sections were incubated overnight at 4ºC with primary antibodies against IL-33 (diluted 1:100, rabbit polyclonal, Medical & Biological Laboratories, Nagoya, Japan), ST2 (diluted 1:100, mouse monoclonal, Medical & Biological Laboratories), mast cell tryptase (diluted 1:1000, mouse monoclonal, Dako), and CD34 (diluted 1:50, mouse monoclonal, Dako). The sections were incubated with secondary antibodies conjugated to a peroxidase-labeled polymer (EnVision™+ system, Dako) at room temperature for 30 min. Immune complexes were detected using 3,3'-diaminobenzidine tetrahydrochloride, and the sections were counterstained with hematoxylin. The specificities of the staining reactions were confirmed using nonimmune serum instead of the primary antibody. 
IL-33 and ST2 expression and mast cell density (MCD)
Two
Microvessel density (MVD)
MVD was calculated by counting the number of vessels stained with CD-34 according to Weidner et al [27] . Three areas with the highest MVD were selected in a 40× to 100× field.
Then, microvessels were counted in the three areas in a 200× field. MVD was calculated as the average of three counts. Any brownish-staining endothelial cell or endothelial cell cluster was considered as a single microvessel.
Statistical analysis
IBM SPSS Statistics version 19 (IBM, Armonk, New York, USA) was used for data analysis. The clinical characteristics of patients in terms of IL-33 and ST2 expression and MCD were analyzed using Fisher's exact test and the chi-square test. The relationship between IL-33 and ST2 expression and MCD was evaluated using Spearman's rank correlation coefficient. Survival curves were evaluated using the Kaplan-Meier method, and differences between curves were analyzed using the log-rank test. IL-33 expression in relation to MVD was analyzed using the Mann-Whitney U test. A p value of <0.05 was considered statistically significant.
Results
IL-33 was detected only in the nuclei of normal epithelial cells, and ST2 was observed most frequently, but faintly, in the membrane and cytoplasm of cells in the prickle cell to horny layers (Fig. 1A and 1B) . In contrast, IL-33 was detected in the nuclei and cytoplasm of SCC cells (Fig. 1C) . ST2 expression was most prominent in the membrane and cytoplasm of the tumor cells (Fig. 1D) . IL-33 and ST2 expression were observed in 100% and 95.1% of the samples, respectively. The mean expression scores for IL-33 and ST2 in the tumor cells were 41.59% ± 23.89% and 22.14% ± 19.29%, respectively.
MCD
MCs were detected by staining with the anti-tryptase antibody in all samples, and they were located in the stroma at the margins of the tumors (Fig. 1E) . The mean MCD was 12.54% ± 11.60%.
Correlation of IL-33 and ST2 expression with MCD
IL-33 expression correlated significantly with ST2 expression (r = 0.558, p < 0.001, Fig.   2A ). IL-33 expression also correlated with MCD (r = 0.626, p < 0.001, Fig. 2B ).
Association of IL-33 and ST2 expression and MCD with disease-free survival
To evaluate the prognostic value of IL-33 and ST2 expression and MCD in patients with tongue SCC, patients were stratified into high and low groups as described in Methods. The median expression scores for IL-33 and ST2 were 46% and 14%, respectively, and 9% for MCD. These scores were used as cutoff values. Of the 81 specimens, 41 were assigned to the high group. Kaplan-Meier survival analysis revealed that the prognosis was poorer for the high IL-33 and ST2 groups than for the low IL-33 and ST2 groups (p = 0.004 and 0.024, respectively, Fig. 3A and 3B) . Similarly, the disease-free survival rate was significantly lower in the high MCD group than in the low MCD group (p = 0.038, Fig. 3C ).
Furthermore, to examine the relationship of the prognosis of the high IL-33 patients with postoperative adjuvant therapy, Kaplan-Meier survival analysis was performed. Of the 41 patients assigned to the high IL-33 group, 14 patients underwent postoperative radiotherapy.
Although the patients with postoperative treatment tended to have better prognosis than those without postoperative treatment, there was no significant difference between the two (p = 0.145 data not shown).
Relationship between clinicopathological features and expression of IL-33, ST2, and
MCD
The relationship between immunohistochemical data and clinicopathological factors of the 81 patients, including age, sex, T classification, N classification, clinical stage, local recurrence, nodal recurrence, and distant metastatic recurrence, was evaluated using Fisher's exact test and the chi-square test (Table 1) . Local recurrence was significantly more frequent among patients in the high IL-33 group than among those in the low IL-33 group. IL-33 and ST2 expression and MCD were significantly associated with nodal recurrence. A higher frequency of nodal recurrence associated significantly with the high IL-33, ST2, and MCD groups, but not with the low groups. There were no other significant differences in clinicopathological features between the low and high IL-33, ST2, and MCD groups.
Relationship between IL-33 expression and MVD
Vascular endothelial cells reacted specifically with the antibody against CD34. The microvessels were detected as scattered structures in the stroma of the tumor (Fig. 1F) .
MVDs in all patients ranged from 7 to 75 (mean, 34.41 ± 16.46). The correlation between IL-33 expression and MVD is shown in Table 2 . MVD was significantly higher in the high IL-33 group than in the low IL-33 group (p < 0.001).
Discussion
Little is known about the role of IL-33 in the pathogenesis and progression of carcinomas [18, 19] . This is the first study, to our knowledge, that demonstrates IL-33 expression in tongue SCC and suggests its role in the progression of this tumor. We detected the expression of IL-33 and ST2 in patients with tongue SCC by immunohistochemistry and found that the expression of IL-33 was significantly correlated with poor prognosis.
We do not go further for the molecular mechanism which is attributable to the prognostic value of IL-33 in this study, however, one of possible mechanism for IL-33-mediated malignant progression could be an activation of ST2 downstream signal transduction such as nuclear factor-κB (NF-κB). The IL-33/ST2 axis leads to activation of NF-κB [8, 20, 28] , which is a key inducer of innate immunity and inflammation and has emerged as an important endogenous tumor promoter [6, 29] . NF-κBactivates the expression of genes encoding inflammatory cytokines, adhesion molecules, enzymes of the prostaglandinsynthesis pathway, inducible nitric oxide synthase, and angiogenic factors. Thus, activation of NF-κB through the IL-33 signaling pathway may cause cancer progression. [8, 20] . High levels of Th2 cytokines are observed in the tumor microenvironment and peripheral blood of patients with certain cancers [30] . Moreover, analysis of ST2-deficient mice demonstrates that the Th2-associated immune response is inhibited in the absence of IL-33/ST2 signaling, leading to delayed induction of mammary tumors and slower tumor growth and progression [31, 32] .
In addition, IL-33 induces angiogenesis and vasopermeability [33] . Our present study reveals that IL-33 expression strongly correlated with MVD and was significantly associated with local and nodal recurrence, but not clinical stage. These results suggest that IL-33 influences the malignant potential of the tumor through the promotion of angiogenesis and activation of ST2 signaling.
We also demonstrate that IL-33 expression significantly correlated with MCD, suggesting that IL-33 contributes to tumor progression by activating MCs. An induction of IL-33 potently activates the innate immune system by inducing pro-inflammatory cytokines and chemokine production through the activation of MCs. It also induces the degranulation of IgE-primed MCs and enhances their maturation and survival [8, 20] . The MCD generally correlates with poor outcome in patients with tongue SCC [34, 35] . Furthermore, other studies reveal that IL-33 activates macrophages, dendritic cells, eosinophils, and neutrophils [8, 20] .
These cells play important roles in enhancing an inflammatory environment that promotes tumor growth in the surrounding tissue [6] . IL-33 may recruit these inflammatory cells to the stroma of the tumor, subsequently enhancing tumor aggressiveness.
In conclusion, the high expression level of IL-33 is a risk factor for poor prognosis in patients with tongue SCC. In the high IL-33 patients, postoperative radiotherapy tended to improve the prognosis. Those patients received postoperative radiotherapy were likely to Differences between the curves were analyzed using the log-rank test. Disease-free survival rates in relation to IL-33 expression (A), ST2 expression (B), and MCD (C). Relationship between clinicopathological features and expression of IL-33, ST2, and MCD 
